NRSN News
NeuroSense Provides Update on Nasdaq Listing Compliance
NeuroSense Provides Update on Nasdaq Listing Compliance NeuroSense Provides Update on Nasdaq Listing CompliancePR NewswireCAMBRIDGE, Mass., Oct. 2, 2026Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional...
PR Newswire
NeuroSense Provides Update on Nasdaq Listing Compliance
NeuroSense Provides Update on Nasdaq Listing Compliance NeuroSense Provides Update on Nasdaq Listing CompliancePR NewswireCAMBRIDGE, Mass., Oct. 2, 2026Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional...
PR Newswire
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities ConferencePR NewswireCAMBRIDGE, Mass., Sept. 28, 2026 Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference...
PR Newswire
NeuroSense Provides Business Update and Progress for the First Half of 2026
NeuroSense Provides Business Update and Progress for the First Half of 2026 NeuroSense Provides Business Update and Progress for the First Half of 2026PR NewswireCAMBRIDGE, Mass., Sept. 25, 2026 CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ --Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the...
PR Newswire
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference PR Newswire CAMBRIDGE, Mass., Sept. 10, 2026 Company presentation on Tuesday, September 15 at 4:30 p.m. ETManagement will be available...
PR Newswire
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS PR Newswire CAMBRIDGE, Mass., Aug. 31, 2026 Three-part program - AI-enabled...
PR Newswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million.
NeuroSense Therapeutics (NASDAQ:NRSN) shares increasedread more...
Benzinga
NeuroSense Issues CEO Letter to Shareholders
NeuroSense Issues CEO Letter to Shareholders NeuroSense Issues CEO Letter to Shareholders PR Newswire CAMBRIDGE, Mass., Aug. 13, 2026 CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ --NeuroSense Therapeutics Ltd.(NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on...
PR Newswire
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada PR Newswire CAMBRIDGE, Mass., Aug. 6, 2026 Final meeting minutes reflect alignment with...
PR Newswire
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS PR Newswire CAMBRIDGE, Mass., July 22, 2026 The planned submission follows alignment with Health Canada on the NDS pathway and is supported...
PR Newswire
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" PR Newswire CAMBRIDGE, Mass., July 6, 2026 Featuring renowned ALS expert Prof...
PR Newswire